Author/Editor		Illini, Oliver; Fabikan, Hannah; Swalduz, Aurélie; Vikström, Anders; Krenbek, Dagmar; Schumacher, Michael; Dudnik, Elizabeth; Studnicka, Michael; Öhman, Ronny; Wurm, Robert; Čufer, Tanja; Mohorčič, Katja; Hochmair, Maximilian J
Title		Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP)
Type		članek
Vol. and No.		, št. Vol. 14
Publication year		2022
Volume		str. 1-22
ISSN		1758-8359 - Therapeutic advances in medical oncology
Language		eng
Abstract		Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal‐epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population in early trials. Methods: We performed a retrospective, international, multicenter efficacy and safety analysis in patients with NSCLC treated with capmatinib in an early access program between March 2019 and December 2021. Results: Data from 81 patients with advanced MET exon 14 mutated NSCLC treated with capmatinib in first- or later-line therapy were analyzed. Median age was 77years (range, 48‐91), 56% were women, 86% had stage IV disease, and 27% had brain metastases. For all patients, the objective response rate (ORR) to capmatinib was 58% (95% CI, 47‐69), whereas it was 68% (95% CI, 50‐82) in treatment-naïve and 50% (95% CI, 35‐65) in pretreated patients. The median progression-free survival was 9.5months (95% CI, 4.7‐14.3), whereas it was 10.6months (95% CI, 5.5‐15.7) in first-line and 9.1months (95% CI, 3.1‐15.1) in pretreated patients. After a median follow-up of 11.0months, the median overall survival was 18.2 months (95% CI, 13.2‐23.1). In patients with measurable brain metastases (n=11), the intracranial ORR was 46% (95% CI, 17‐77). Capmatinib showed a manageable safety profile. Grade⩾3 treatment-related adverse events included peripheral edema (13%), elevated creatinine (4%), and elevated liver enzymes (3%). Conclusion: In patients with MET exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting.
Descriptors		Carcinoma, non-small cell lung Molecular targeted therapy Nedrobnocelični karcinom pljuč Molekularna tarčna terapija Drug therapy Genetics Terapija z zdravili Genetika
Keywords		podatki iz resničnega življenja capmatinib tarčna terapija real-world data capmatinib targeted therapy